Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Paclitaxel in Breast Cancer
NCT02041429Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in breast cancer, inflammatory breast cancer (IBC) and triple negative breast cancer (TNBC) (5 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 8 weeks and Dose Limiting Toxicity at 8 weeks. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
breast cancerinflammatory breast cancer (IBC)triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02041429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041429.